Journal
NATURE IMMUNOLOGY
Volume 15, Issue 5, Pages 431-438Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ni.2850
Keywords
-
Categories
Funding
- Leukaemia Foundation of Australia (C. J. C.)
- Monash University Faculty of Medicine
- National Health and Medical Research Council [1013667, 1044392, 628623]
- US National Institutes of Health [P30AR048335]
Ask authors/readers for more resources
CD96, CD226 (DNAM-1) and TIGIT belong to an emerging family of receptors that interact with nectin and nectin-like proteins. CD226 activates natural killer (NK) cell-mediated cytotoxicity, whereas TIGIT reportedly counterbalances CD226. In contrast, the role of CD96, which shares the ligand CD155 with CD226 and TIGIT, has remained unclear. In this study we found that CD96 competed with CD226 for CD155 binding and limited NK cell function by direct inhibition. As a result, Cd96(-/-) mice displayed hyperinflammatory responses to the bacterial product lipopolysaccharide (LPS) and resistance to carcinogenesis and experimental lung metastases. Our data provide the first description, to our knowledge, of the ability of CD96 to negatively control cytokine responses by NK cells. Blocking CD96 may have applications in pathologies in which NK cells are important
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available